Quantification of tau load in Alzheimer’s disease clinical trials using positron emission tomography

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

Alzheimer’s disease is a neurodegenerative condition that is neuropathologically characterized by the presence of amyloid-β plaques and neurofibrillary tangles consisting of tau. Recently, several positron emission tomography (PET) tracers have been developed that yielded promising initial results. In this chapter, we discuss how tau PET can be used in the context in clinical trials. We argue that simplified reference tissue models based on dynamic data acquisition are most suitable for accurately measuring changes in tau pathology in trials tailored to reduce cerebral tau load. Therefore, we discuss the importance of tracer kinetic modeling and describe in detail how a reliable measurement of specific binding can be obtained.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages221-229
Number of pages9
DOIs
Publication statusPublished - 1 Jan 2018

Publication series

NameMethods in Molecular Biology
Volume1750
ISSN (Print)1064-3745

Cite this

@inbook{7c8ce2555d3b400a9842ab66e5bed484,
title = "Quantification of tau load in Alzheimer’s disease clinical trials using positron emission tomography",
abstract = "Alzheimer’s disease is a neurodegenerative condition that is neuropathologically characterized by the presence of amyloid-β plaques and neurofibrillary tangles consisting of tau. Recently, several positron emission tomography (PET) tracers have been developed that yielded promising initial results. In this chapter, we discuss how tau PET can be used in the context in clinical trials. We argue that simplified reference tissue models based on dynamic data acquisition are most suitable for accurately measuring changes in tau pathology in trials tailored to reduce cerebral tau load. Therefore, we discuss the importance of tracer kinetic modeling and describe in detail how a reliable measurement of specific binding can be obtained.",
keywords = "Alzheimer’s disease (AD), AV1451, Clinical trial, Positron emission tomography (PET), Tau",
author = "Tessa Timmers and {van Berckel}, {Bart N.M.} and Lammertsma, {Adriaan A.} and Rik Ossenkoppele",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-7704-8_15",
language = "English",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "221--229",
booktitle = "Methods in Molecular Biology",

}

Quantification of tau load in Alzheimer’s disease clinical trials using positron emission tomography. / Timmers, Tessa; van Berckel, Bart N.M.; Lammertsma, Adriaan A.; Ossenkoppele, Rik.

Methods in Molecular Biology. Humana Press Inc., 2018. p. 221-229 (Methods in Molecular Biology; Vol. 1750).

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

TY - CHAP

T1 - Quantification of tau load in Alzheimer’s disease clinical trials using positron emission tomography

AU - Timmers, Tessa

AU - van Berckel, Bart N.M.

AU - Lammertsma, Adriaan A.

AU - Ossenkoppele, Rik

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Alzheimer’s disease is a neurodegenerative condition that is neuropathologically characterized by the presence of amyloid-β plaques and neurofibrillary tangles consisting of tau. Recently, several positron emission tomography (PET) tracers have been developed that yielded promising initial results. In this chapter, we discuss how tau PET can be used in the context in clinical trials. We argue that simplified reference tissue models based on dynamic data acquisition are most suitable for accurately measuring changes in tau pathology in trials tailored to reduce cerebral tau load. Therefore, we discuss the importance of tracer kinetic modeling and describe in detail how a reliable measurement of specific binding can be obtained.

AB - Alzheimer’s disease is a neurodegenerative condition that is neuropathologically characterized by the presence of amyloid-β plaques and neurofibrillary tangles consisting of tau. Recently, several positron emission tomography (PET) tracers have been developed that yielded promising initial results. In this chapter, we discuss how tau PET can be used in the context in clinical trials. We argue that simplified reference tissue models based on dynamic data acquisition are most suitable for accurately measuring changes in tau pathology in trials tailored to reduce cerebral tau load. Therefore, we discuss the importance of tracer kinetic modeling and describe in detail how a reliable measurement of specific binding can be obtained.

KW - Alzheimer’s disease (AD)

KW - AV1451

KW - Clinical trial

KW - Positron emission tomography (PET)

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85043469619&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7704-8_15

DO - 10.1007/978-1-4939-7704-8_15

M3 - Chapter

T3 - Methods in Molecular Biology

SP - 221

EP - 229

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -